{"page":{"totalFilteredElements":90},"studies":[{"active":true,"description":"<div>A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination with</div><div>Daratumumab, Lenalidomide, and Dexamethasone with or without Bortezomib as</div><div>Induction Therapy and Teclistamab in Combination with Daratumumab and</div><div>Lenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma</div><div><br /></div>","eudractNumber":"2022-001186-12","id":8497,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05695508","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2022-12-01T15:24:49+01:00","shortTitle":"DSMM XX [GMMG-HD10], MajesTEC-5","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Nicht-interventionelles, prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen und follikul&#228;ren Lymphomen&#160;inkl. Biomaterial-Sammlung f&#252;r Patienten mit Marginalzonenlymphom","eudractNumber":null,"id":4372,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2018-04-06T10:55:50+02:00","shortTitle":"Deutsches Register für Marginalzonenlymphome und Follikuläre Lymphome - MZoL- FL Register","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nicht-interventionelles, prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen und follikul&#228;ren Lymphomen&#160;inkl. Biomaterial-Sammlung f&#252;r Patienten mit Marginalzonenlymphom","eudractNumber":null,"id":7900,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2021-02-04T15:27:44+01:00","shortTitle":"Deutsches Register für Marginalzonenlymphome und Follikuläre Lymphome - MZoL-FL Register","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p class=\"MsoNormal\">Deutsches Register f&#252;r Stammzelltransplantationen / EBMT\nRegistry on stem cell transplantation (DRST)</p>","eudractNumber":null,"id":6852,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2005-01-03T13:23:27+01:00","shortTitle":"Deutsches Register für Stammzelltransplantationen - MZoL-FL Register / EBMT Registry on stem cell transplantation","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Randomized phase II trial for patients with newly diagnosed low-risk multiple myeloma to evaluate the benefit of 6 cycles of isatuximab with lenalidomide/ bortezomib/ dexamethasone (I-VRD) followd by maintenance therapy with lenalidomide and isatuximab randomized in comparison with therapy consisting of 3 cycles of I-VRD followd standard of care intensification followed by maintenance therapy with lenalidomide and isatuximab<div><br /></div><div>Short title: Expression-linked and R-Iss-Adapted Stratification for first line therapy in multiple myeloma patients (ELIAS)</div>","eudractNumber":"2020-005102-26","id":9532,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05665140","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-07-01T12:46:18+02:00","shortTitle":"ELIAS","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div><br /></div>Mantelzell-Register, Einschluss aller Linien","eudractNumber":null,"id":7531,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2021-11-01T12:47:28+01:00","shortTitle":"EMCL Register","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div>A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued</div><div>Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients</div>","eudractNumber":"2024-519827-16-00","id":11504,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06932562","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-11-10T09:57:13+01:00","shortTitle":"EMN 39","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase II Trial of Teclistamab in participants with previously treated Immunoglobulin Light-Chain (AL) Amyloidosis","eudractNumber":"2024-519191-90-00","id":11509,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06649695","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-07-25T13:24:44+02:00","shortTitle":"EMN 40","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Einzelzellanalysen kutane Malignome&#8220; ( Charakterisierung von kutanen Malignomen und deren Mikroumgebung durch Einzelzellanalysen von Tumor, Blut und Lymphknotengewebe)&#160;","eudractNumber":null,"id":11303,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"hau2","name":"Basaliom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-03-25T11:24:44+01:00","shortTitle":"Einzelzellanalysen kutane Malignome","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Tumor-assoziierte Fatigue und Symptomcluster &#8211; Effekte von virtuellem, imaginiertem und klassischem Waldbaden auf das Befinden von Krebs&#252;berlebenden &#8211; eine randomisierte kontrollierte Studie<br />Cancer-related fatigue and symptom clusters &#8211; Effects of virtual, imagined and real-life nature-based therapy in cancer survivors &#8211; a randomized controlled trial<br />FOREST - Studie","eudractNumber":null,"id":10999,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"pro","name":"Prostatakrebs"},{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"uro2","name":"Tumoren der ableitenden Harnwege (Nierenbecken, Ureter, Harnblase, Harnröhre)"},{"id":"uro3","name":"Hodenkarzinom"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"gio4","name":"Weitere Tumoren des Verdauungstraktes (z.B. Gastrointestinale Stromatumoren, GIST)"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"giu4","name":"Weitere Tumoren des Verdauungstraktes (z.B. Gastrointestinale Stromatumoren, GIST)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno1","name":"Mundhöhlenkarzinom, Rachenkarzinom, inkl. Mundboden- und Zungengrundkarzinom"},{"id":"hno2","name":"Kehlkopfkrebs (Larynxkarzinom)"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"sch","name":"Schilddrüsenkarzinom"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"zns4","name":"Weitere Hirntumoren"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"hau2","name":"Basaliom"},{"id":"hau3","name":"Spinaliom (Plattenepithelkarzinom)"},{"id":"hau4","name":"Merkelzellkarzinom"},{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym2","name":"Morbus Hodgkin"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"},{"id":"leu4","name":"Weitere hämatologische Neoplasien"}],"mutations":[],"nctNumber":"NCT06931132","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-02-01T10:56:01+01:00","shortTitle":"FOREST","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}